Table 2.

Antimicrobial susceptibilities of clinical isolates and transconjugants

Strain no. (pI of ESBL in R+strains)aMIC (μg/ml)
AmpicillinPiperacillinPiperacillin
+ tazobactam
CefotaximeCefotaxime
+ clavulanate
Cefotaxime
+ tazobactam
CeftazidimeCeftazidime
+ clavulanate
Ceftazidime
+ tazobactam
AztreonamAztreonam
+ clavulanate
Aztreonam
+ tazobactam
CefoxitinImipenem
K. pneumoniae
 L-267>512>5128320.250.251280.50.51280.1250.25160.125
 L-372>512>512880.1250.125640.50.5640.250.2540.125
 L-380>512>512880.1250.125640.50.5640.250.2540.125
 L-491>512>5128160.250.251280.50.51280.250.2580.25
 L-577>512>512880.1250.1251280.50.51280.250.2580.125
 L-439>512>5124320.250.251280.50.51280.1250.2520.25
 L-414>512>5124160.060.061280.50.52560.1250.520.125
 L-251>512>5128320.060.5512125120.1250.580.125
 L-95>512>51216320.1250.5512285120.125480.125
 L-352>5125124160.1250.5256112560.060.2540.25
 L-902>512>51216640.1250.5512285120.25280.125
E. coliL-867>512>51216641646416812888640.125
Transconjugants
 R+ L-267 (6.0)>5122560.58≤0.03≤0.03320.1250.125320.060.0620.25
 R+ L-372 (6.0)>5122560.58≤0.030.06160.1250.125320.060.0620.25
 R+ L-380 (6.0)>5125120.516≤0.03≤0.03320.1250.125640.060.0620.25
 R+ L-491 (6.0)>5122560.58≤0.03≤0.03160.1250.125320.060.0640.25
 R+ L-577 (6.0)>5122560.58≤0.03≤0.03160.1250.125320.060.0620.25
 R+ L-439 (8.2)2563212≤0.03≤0.03160.060.125320.060.0620.25
 R+ L-414 (8.2)2563212≤0.03≤0.03160.060.12532≤0.03≤0.0320.25
 R+ L-251 (8.2)512640.54≤0.03≤0.03320.060.125640.060.0620.25
 R+ L-867 (6.0)>5121280.52≤0.03≤0.03160.060.125320.06≤0.0320.25
E. coli A15 (recipient)20.50.5≤0.03≤0.03≤0.030.060.060.060.06≤0.03≤0.0320.25
  • a R+, transconjugants.